NCT00398814View on ClinicalTrials.gov

Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

October 31, 2011

Conditions
Renal CancerTumors
Interventions
DRUG

Perifosine

For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.

DRUG

Sorafenib

For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.

Sponsors

Lead Sponsor

AEterna Zentaris
All Listed Sponsors
lead

AEterna Zentaris

INDUSTRY